| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Enjoy the freedom of a pain-free, active lifestyle with help from our orthopedic specialists at OrthoArizona. Learn more today!
Champions Oncology is a company that develops technology solutions and services for personalizing the development and use of oncology drugs. Their technology-enabled research platforms empower biopharma to create a comprehensive understanding of tumor ...
SwitchGear Genomics (Main) is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Anadys Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.